{
  "first_published_at": "2012-09-25", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON185630", 
  "title": "Levofloxacin: some indications restricted", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\", \"respiratory-disease-allergy\", \"dermatology\", \"dentistry\"], \"Audience:\": [\"Primary care\", \"Secondary care\", \"Dentists\"], \"Therapeutic area:\": [\"Infectious disease\", \"Respiratory disease and allergy\", \"Dermatology\"]}", 
  "_document_number": 98, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "infectious-disease", 
    "respiratory-disease-allergy", 
    "dermatology", 
    "dentistry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Levofloxacin: some indications restricted</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Levofloxacin (a fluoroquinolone antibiotic) may only be considered in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia or complicated skin and soft tissue infections when other medicines cannot be prescribed, or have been ineffective.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<br />\nLevofloxacin (a fluoroquinolone antibiotic) may only be considered in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia or complicated skin and soft tissue infections when other medicines cannot be prescribed, or have been ineffective.<br />\n<br />\nThis restriction resulted from a review of overall efficacy and safety data, which suggested that the safety profile of levofloxacin was unfavourable as first-line treatment for these indications. The risks contributing to this assessment included serious hepatotoxicity, cardiac arrhythmia, severe skin reactions and tendon rupture.<br />\n<br />\nOther licensed indications for oral and intravenous levofloxacin remain unchanged.<br />\n<br />\nProduct information for all levofloxacin products will be updated with the recommendations. Official guidance on the appropriate use of antibiotics and the prevalence of resistance (such as <a href=\"http://www.nice.org.uk/#panel3\" target=\"_blank\">NICE guidance</a>) should be considered when prescribing levofloxacin.<br />\n<br />\n<strong>Further information:</strong><br />\n<br />\nBNF section 5.1: <a href=\"http://www.medicinescomplete.com/mc/bnf/current/201584.htm\" target=\"_blank\">Antibacterial drugs</a><br />\n<br />\n<a href=\"http://www.brit-thoracic.org.uk/guidelines.aspx\" target=\"_blank\">British Thoracic Society Guidelines</a><br />\n<br />\n<em>Article citation: Drug Safety Update September 2012, vol 6, issue 2: S2</em>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<br>\nLevofloxacin (a fluoroquinolone antibiotic) may only be considered in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia or complicated skin and soft tissue infections when other medicines cannot be prescribed, or have been ineffective.<br>\n<br>\nThis restriction resulted from a review of overall efficacy and safety data, which suggested that the safety profile of levofloxacin was unfavourable as first-line treatment for these indications. The risks contributing to this assessment included serious hepatotoxicity, cardiac arrhythmia, severe skin reactions and tendon rupture.<br>\n<br>\nOther licensed indications for oral and intravenous levofloxacin remain unchanged.<br>\n<br>\nProduct information for all levofloxacin products will be updated with the recommendations. Official guidance on the appropriate use of antibiotics and the prevalence of resistance (such as <a href=\"http://www.nice.org.uk/#panel3\" target=\"_blank\">NICE guidance</a>) should be considered when prescribing levofloxacin.<br>\n<br>\n<strong>Further information:</strong><br>\n<br>\nBNF section 5.1: <a href=\"http://www.medicinescomplete.com/mc/bnf/current/201584.htm\" target=\"_blank\">Antibacterial drugs</a><br>\n<br>\n<a href=\"http://www.brit-thoracic.org.uk/guidelines.aspx\" target=\"_blank\">British Thoracic Society Guidelines</a><br>\n<br>\n<em>Article citation: Drug Safety Update September 2012, vol 6, issue 2: S2</em>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-09-01", 
  "date_last_modified": "2013-02-05", 
  "_assets": [], 
  "_item_id": 98, 
  "summary": "", 
  "body": "Article date: September 2012   \nLevofloxacin (a fluoroquinolone antibiotic) may only be considered in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia or complicated skin and soft tissue infections when other medicines cannot be prescribed, or have been ineffective.  \n  \nThis restriction resulted from a review of overall efficacy and safety data, which suggested that the safety profile of levofloxacin was unfavourable as first-line treatment for these indications. The risks contributing to this assessment included serious hepatotoxicity, cardiac arrhythmia, severe skin reactions and tendon rupture.  \n  \nOther licensed indications for oral and intravenous levofloxacin remain unchanged.  \n  \nProduct information for all levofloxacin products will be updated with the recommendations. Official guidance on the appropriate use of antibiotics and the prevalence of resistance (such as [NICE guidance](http://www.nice.org.uk/#panel3)) should be considered when prescribing levofloxacin.  \n  \nFurther information:  \n  \nBNF section 5.1: [Antibacterial drugs](http://www.medicinescomplete.com/mc/bnf/current/201584.htm)  \n  \n[British Thoracic Society Guidelines](http://www.brit-thoracic.org.uk/guidelines.aspx)  \n  \nArticle citation: Drug Safety Update September 2012, vol 6, issue 2: S2\n"
}